Form 4: Lipella Pharmaceuticals CEO Gains Voting Power Over Spartan Capital's Shares via Irrevocable Proxy

Lipella Pharmaceuticals' CEO, Jonathan Kaufman, secures voting control over shares held by Spartan Capital Securities and its affiliates through an irrevocable proxy agreement.

Summary

• Lipella Pharmaceuticals has entered into agreements with Spartan Capital Securities, including a consulting agreement and a placement agent agreement.
• As part of these agreements, Lipella is issuing Series C Convertible Preferred Stock, common stock purchase warrants, and common stock to Spartan Capital.
• To induce Lipella into these agreements, Spartan Capital has granted an irrevocable proxy and power of attorney to Lipella's CEO, Jonathan Kaufman.
• This proxy gives Kaufman the power to vote the shares held by Spartan Capital and its affiliates.
• The proxy is effective as of December 20, 2024, and covers Consultant Shares, Conversion Shares, and Warrant Shares.
• The proxy terminates upon the registration of the reoffer and resale of the Conversion Shares and Warrant Shares, or upon disposition of shares to a non-Attribution Party.
• Kaufman, as of February 28, 2025, has voting power over 441,933 shares of Series C Voting Convertible Preferred Stock and 125,833 Common Stock Purchase Warrants held by Spartan and its affiliates.
• The shares are subject to an irrevocable proxy and power of attorney, effective December 20, 2024, between Kaufman and Spartan Capital Securities, LLC.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The agreement provides clarity on voting control and aligns interests, but also introduces potential risks related to concentrated power.

Positives

• The irrevocable proxy strengthens the CEO's control over the company's voting power.
• The agreement ensures alignment between Spartan Capital's interests and the company's leadership.
• The proxy is coupled with an interest, making it legally robust and difficult to revoke.

Negatives

• The concentration of voting power in the hands of the CEO could potentially limit shareholder influence.
• The restrictions on Spartan Capital's ability to transfer shares could limit their flexibility.

Risks

• Potential conflicts of interest could arise if the CEO's interests diverge from those of other shareholders.
• The restrictions on share transfers could impact the liquidity of Spartan Capital's investment.
• The termination conditions of the proxy could lead to shifts in voting power in the future.

Future Outlook

The Company undertakes to include the maximum possible number of Conversion Shares and Warrant Shares in the initial registration statement filed in connection with the Offering and in each subsequent registration statement, as needed, and agrees to lift all Transfer and notice restrictions six months after any issuance if such Conversion Shares and Warrant Shares are not then registered for resale.

Management Comments

• Spartan is executing this Irrevocable Proxy as a material inducement for the Corporations entering into the Consulting Agreement and the Placement Agent Agreement.

Industry Context

The use of irrevocable proxies is a common practice in corporate finance to ensure stability and control, particularly in situations involving significant investments or strategic partnerships. This arrangement is similar to those seen in venture capital deals where investors receive board seats and voting rights proportional to their investment.

Comparison to Industry Standards

• Similar arrangements are common in the biotech industry, where companies often rely on strategic partnerships and financing agreements to fund research and development.
• The terms of the proxy, including the termination conditions and transfer restrictions, are generally consistent with industry standards for similar agreements.
• Compared to other companies with similar market capitalizations, Lipella's reliance on consulting agreements and placement agent agreements is not uncommon, but the specific terms of the irrevocable proxy should be carefully evaluated.

Stakeholder Impact

• Shareholders: Potential impact on voting power and influence.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• Registration of the reoffer and resale of the Conversion Shares and Warrant Shares.
• Potential transfer of Consultant Shares, Conversion Shares or Warrant Shares by Spartan (or any other Attribution Party) to an Attribution Party upon such transferees delivery of a completed and executed Joinder Agreement.
• Filing of registration statements to include the maximum possible number of Conversion Shares and Warrant Shares.

Key Dates